Please ensure Javascript is enabled for purposes of website accessibility
George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

lung xray

Why RedHill Biopharma Stock Is Getting Crushed Today

A clinical failure is sending shareholders to the exits this morning.


Why Dynavax Technologies Stock Is Sinking Today

A lost supply agreement for a partner's COVID-19 vaccine is hurting the biotech's shares today.

sad senior

Why Biogen Stock Is Slipping Today

Aduhelm's commercial launch isn't off to a strong start.

elderly cancer patient

Why eFFECTOR Therapeutics Stock Is Heating Up Today

The biotech's novel cancer platform is fueling buyout speculation on social media today.

angry man

Why Axsome Therapeutics Stock Cratered in August

An unexpected regulatory setback weighed heavily on the biotech's shares last month.

lymphocytes and cancer

Why Curis Stock Perked Up in August

The biotech's shares rode the wave of buyout speculation higher last month.


Why Kadmon Holdings Stock Is Rocketing Higher Today

Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan.

T cells

Why Adaptimmune Therapeutics Stock Is Bolting Higher Today

A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.

lymphocytes and cancer

Why Adaptimmune Therapeutics Stock Is Spiking Today

The hunt for the next biotech buyout play is apparently underway.

female cancer patient

Why Trillium Therapeutics Stock Is Skyrocketing Today

Pfizer may have gotten a fantastic deal on this clinical-stage oncology company.

man at laptop

Why Axsome Therapeutics Stock Is Crashing Today

An unexpected regulatory setback is weighing on the biotech's shares today.


Why Ardelyx Stock Is Getting Crushed Today

The FDA doesn't appear to be impressed by the biotech's experimental kidney disease drug.

liver disease

Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021

The biotech can't seem to catch a break.

cancer patient

Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021

The biotech's shares have definitely lost their shine in 2021.

heart checkup

Why Amarin Stock Is Sinking Today

The biotech's attempt to revive Vascepa's U.S. patent protection appears to be at a dead end.

doctor money

2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin

These unloved cancer stocks should dramatically outperform Dogecoin over the long haul.


Why ResMed Stock Exploded Higher This Week

A competitor's misfortune could be a big opportunity for the medical device giant.

cancer cells

Why Agenus Stock Is Marching Higher Today

The biotech took a major step toward becoming a commercial-stage cancer company.

elderly covid patient

Why CureVac Stock Is Getting Crushed Today

The biotech's COVID-19 vaccine candidate no longer appears to be viable.

researcher inspecting vial

Why Viking Therapeutics Stock Briefly Popped Today

An early-stage study gave investors reasons to cheer this morning.